Next Article in Journal
Advances in Nutritional Research on Regulatory T-Cells
Next Article in Special Issue
A Randomised Cross-Over Pharmacokinetic Bioavailability Study of Synthetic versus Kiwifruit-Derived Vitamin C
Previous Article in Journal
Citrus medica “Otroj”: Attenuates Oxidative Stress and Cardiac Dysrhythmia in Isoproterenol-Induced Cardiomyopathy in Rats
Previous Article in Special Issue
A Randomized Steady-State Bioavailability Study of Synthetic versus Natural (Kiwifruit-Derived) Vitamin C
 
Search for Articles:
Title / Keyword
Author / Affiliation
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
Journals
Nutrients
Volume 5
Issue 11
10.3390/nu5114284
nutrients-logo
Submit to this Journal Review for this Journal Edit a Special Issue
► Article Menu

Article Menu

share announcement thumb_up
...
textsms
...
Open AccessReview

Synthetic or Food-Derived Vitamin C—Are They Equally Bioavailable?

by Anitra C. Carr * and Margreet C. M. Vissers
Centre for Free Radical Research, Department of Pathology and Biomedical Science, University of Otago, Christchurch, P.O. Box 4345, Christchurch 8140, New Zealand
*
Author to whom correspondence should be addressed.
Nutrients 2013, 5(11), 4284-4304; https://doi.org/10.3390/nu5114284
Received: 30 August 2013 / Revised: 22 September 2013 / Accepted: 14 October 2013 / Published: 28 October 2013
(This article belongs to the Special Issue Vitamin C and Human Health)
Download PDF
Browse Figure
Cite This Paper

Abstract

Vitamin C (ascorbate) is an essential water-soluble micronutrient in humans and is obtained through the diet, primarily from fruits and vegetables. In vivo, vitamin C acts as a cofactor for numerous biosynthetic enzymes required for the synthesis of amino acid-derived macromolecules, neurotransmitters, and neuropeptide hormones, and is also a cofactor for various hydroxylases involved in the regulation of gene transcription and epigenetics. Vitamin C was first chemically synthesized in the early 1930s and since then researchers have been investigating the comparative bioavailability of synthetic versus natural, food-derived vitamin C. Although synthetic and food-derived vitamin C is chemically identical, fruit and vegetables are rich in numerous nutrients and phytochemicals which may influence its bioavailability. The physiological interactions of vitamin C with various bioflavonoids have been the most intensively studied to date. Here, we review animal and human studies, comprising both pharmacokinetic and steady-state designs, which have been carried out to investigate the comparative bioavailability of synthetic and food-derived vitamin C, or vitamin C in the presence of isolated bioflavonoids. Overall, a majority of animal studies have shown differences in the comparative bioavailability of synthetic versus natural vitamin C, although the results varied depending on the animal model, study design and body compartments measured. In contrast, all steady state comparative bioavailability studies in humans have shown no differences between synthetic and natural vitamin C, regardless of the subject population, study design or intervention used. Some pharmacokinetic studies in humans have shown transient and small comparative differences between synthetic and natural vitamin C, although these differences are likely to have minimal physiological impact. Study design issues and future research directions are discussed.
Keywords: ascorbate; dietary vitamin C; bioavailability; animal studies; human studies; bioflavonoids ascorbate; dietary vitamin C; bioavailability; animal studies; human studies; bioflavonoids

1. Introduction

Vitamin C (ascorbate) is an essential water-soluble micronutrient in humans and is obtained through the diet primarily from fruits and vegetables [1]. In vivo, it acts as a cofactor for numerous biosynthetic enzymes required for the synthesis of amino acid-derived macromolecules, neurotransmitters and neuropeptide hormones [2], and for various hydroxylases involved in the regulation of gene transcription and epigenetics [3,4]. Vitamin C is concentrated from the plasma into the body’s organs and is found in particularly high concentrations in the pituitary and adrenal glands and in the corpus luteum [5], although skeletal muscle, brain, and liver comprise the largest body pools [6]. Most animals can synthesize vitamin C from glucose in the liver [7]; however, humans and a small selection of animal species have lost the ability to synthesize vitamin C due to mutations in the gene encoding l-gulono-γ-lactone oxidase, the terminal enzyme in the vitamin C biosynthetic pathway [8]. Therefore, an adequate and regular dietary intake is essential to prevent hypovitaminosis C and the potentially fatal deficiency disease, scurvy [9].
In the mid 1700s the Royal Navy surgeon James Lind carried out controlled dietary trials and determined that citrus fruit could cure individuals with scurvy (reviewed in [10]). However, it wasn’t until the early 1900s that experimental scurvy was first produced in guinea pigs through dietary restriction and shown to be prevented by feeding the animals fresh fruits and vegetables. In the early 1930s vitamin C was isolated from fruit and vegetables and adrenal cortex and was named “hexuronic acid”, which was shown to cure scurvy in guinea pigs and was subsequently renamed ascorbic acid to reflect its anti-scorbutic properties. Vitamin C was first chemically synthesized in 1933 [10] and, since the mid 1930s, the question of the comparative bioavailability of synthetic versus natural, food-derived vitamin C in animal models and human subjects has been a point of consideration.
The bioavailability of dietary vitamin C represents the proportion of the micronutrient that is absorbed by the intestines and is available for metabolic processes within the body. In vivo vitamin C levels are a function of uptake, metabolism, and excretion (see [11] for an excellent review of these processes). Vitamin C is actively transported into the body via two sodium-dependent vitamin C transporters, SVCT1 and SVCT2 [12,13]. These transporters exhibit different tissue distributions and uptake kinetics. SVCT1 is expressed in epithelial tissues and is primarily responsible for intestinal uptake and renal reabsorption of vitamin C, the latter helping to maintain whole body homeostasis [13]. SVCT2 is expressed in specialized and metabolically active tissues and is required for delivery of vitamin C to tissues with a high demand for the vitamin either for enzymatic reactions [2] and/or to help protect these tissues from oxidative stress [13]. Both of these transporters show significantly more affinity for the l- versus d-isoform of vitamin C (Figure 1) [12,14], and this selectivity likely explains earlier observations of significantly lower tissue accumulation and anti-scorbutic activity of d-ascorbic acid in guinea pigs [15,16]. Although d-ascorbic acid is a commonly added food preservative [17], administration of d- and l-ascorbic acid together does not affect the bioavailability of the latter in humans [18].
Through its action as a reducing agent and antioxidant, ascorbate undergoes one and two electron oxidations to produce the ascorbyl radical and dehydroascorbic acid (DHA) (Figure 1). Recent research has shown that DHA can be taken up by the facilitative glucose transporters GLUT2 and GLUT8 in the small intestine [19]. Cells are also able to transport DHA via GLUT1 and GLUT3 [20,21], followed by intracellular reduction to ascorbate [22,23]. However, transport via the GLUTs is in competition with glucose which is at relatively high concentrations throughout the body and although different fruits and vegetables have been shown to contain relatively high amounts of DHA [24], the in vivo contribution of DHA is uncertain due to its minimal circulating and organ levels [25,26] (although white blood cells may be an exception to this) [27,28].
Nutrients 05 04284 g001 1024
Figure 1. Vitamin C in its reduced form (ascorbic acid), shown as both its l- and d-isomers, and its two electron oxidation form (dehydroascorbic acid, DHA). DHA can be readily reduced back to ascorbic acid in vivo via both chemical and enzymatic pathways [23].
Figure 1. Vitamin C in its reduced form (ascorbic acid), shown as both its l- and d-isomers, and its two electron oxidation form (dehydroascorbic acid, DHA). DHA can be readily reduced back to ascorbic acid in vivo via both chemical and enzymatic pathways [23].
Nutrients 05 04284 g001
Synthetic and food-derived vitamin C is chemically identical. However, fruit and vegetables are rich in numerous micronutrients (vitamins and minerals), dietary fiber, and phytochemicals (e.g., bioflavonoids), and the presence of some of these may affect the bioavailability of vitamin C. Vitamin C has long been known to interact with vitamin E by reducing the tocopheroxyl radical and regenerating native tocopherol [29]. Some fruit, such as kiwifruit, contain relatively high amounts of vitamin E and one animal study has indicated that vitamin E is able to preserve vitamin C in vivo [30]. Food-derived (and synthetic) vitamin C is well known to increase non-heme iron uptake and body status, likely via its ability to reduce iron from its ferric to ferrous state [31,32]. However, whether iron can affect vitamin C bioavailability is less clear [33,34,35]. Although iron has been shown to increase the uptake of vitamin C in cultured intestinal cells [33], human intervention studies have shown no effect of iron intake on vitamin C bioavailability [34,35]. One study has indicated that specific dietary fibers, such as hemicellulose and pectin, may affect the excretion of vitamin C [36], however, their influence on vitamin C uptake was not determined.
Plant-derived flavonoids have been of interest since the mid 1930s, when they were initially referred to as “vitamin P”, primarily due to their effect on vascular permeability [37]. At the time, there was much debate in the literature regarding the role of “vitamin P” in experimental [38,39,40,41,42] and human scurvy [37,43,44,45]. Flavonoids can act as antioxidants via direct scavenging of free radicals [46,47] and/or chelation of redox-active metal ions [48,49]. As a result, it has been suggested that flavonoids may “spare” vitamin C and, thus, increase its bioavailability. Flavonoids have been shown to inhibit the in vitro oxidation of vitamin C [48,49,50,51], however, the in vivo relevance of metal-ion mediated oxidation of vitamin C is likely to be minimal as free metal ions are largely sequestered in the body [52]. Whether flavonoids can affect vitamin C uptake in vivo is uncertain due to the low plasma bioavailability of these compounds [53]. Thus, any interaction of flavonoids with vitamin C would be expected to occur primarily in the intestinal lumen prior to active uptake.
Of note, several in vitro studies have shown that various flavonoids can inhibit vitamin C and DHA uptake by their respective transporters. The flavonoid quercetin can reversibly inhibit SVCT1 expressed in Xenopus oocytes [54] and limited data from an animal model indicates that this may occur in vivo [54]. Quercetin and myricetin can inhibit the uptake of vitamin C and DHA into cultured monocytic (HL-60 and U937) and lymphocytic (Jurkat) cells via inhibition of GLUT1 and GLUT3 [55] and possibly also SVCT2, which is expressed in leukocytes [56]. Quercetin and phloretin can also inhibit the intestinal GLUT2 and GLUT8 transporters [19]. Thus, based on the above in vitro studies, it is unclear whether flavonoids will enhance in vivo vitamin C bioavailability through a sparing action, or decrease its bioavailability through inhibiting vitamin C transporters.
The effect of various purified flavonoids or flavonoid-rich fruits and vegetables on vitamin C bioavailability in different animal models and human subjects is discussed below. To test comparative vitamin C bioavailability, both steady-state and pharmacokinetic models have been used. The former monitors ascorbate levels in blood and/or urine following a number of weeks of supplementation, while the latter monitors transient changes in plasma levels and/or urinary excretion over the hours following ingestion of the vitamin C-containing test substance. The gold standard for analysis of vitamin C is HPLC with coulometric electrochemical detection due to its sensitivity and specificity [57]. Early studies, however, were limited primarily to colourimetric methods based on reduction of ferric iron compounds and are prone to interference by numerous other substances [57].

2. Vitamin C Bioavailability Studies Using Animal Models

There are a number of benefits to the use of animal models to investigate vitamin C bioavailability, particularly the ease of diet control and the ability to obtain tissues not normally accessible in human studies. However, results can vary widely depending on the animal model used and the different treatment and analytical methodologies employed. It should also be noted that not all of the animal models that have been used are naturally vitamin C deficient. The animal models of choice are the naturally vitamin C deficient guinea pig, and genetically scorbutic animal models, such as the Osteogenic Disorder Shionogi (ODS) rat [58], the l-gulono-γ-lactone oxidase (Gulo−/−) knockout mouse [59], and the spontaneous bone fracture (sfx) mouse [60]. Although animal studies can provide useful information, translation of the findings to humans should always proceed with caution.
Studies investigating the comparative bioavailability of synthetic versus natural vitamin C in animal models are shown in Table 1. Studies carried out in guinea pigs showed enhanced uptake of vitamin C into specific organs (e.g., adrenals and spleen) in the presence of flavonoid-rich juices/extracts or purified plant flavonoids (e.g., hesperidin, rutin, and catechin) [42,61,62,63,64]. Vinson and Bose [65] carried out a pharmacokinetic study in guinea pigs and found a 148% increase in the area under the plasma ascorbate concentration-time curve when administered as citrus fruit media. They also noted that the citrus fruit group demonstrated delayed plasma vitamin C uptake compared with the synthetic vitamin C group [65]. Cotereau et al. [42] reported that animals given both vitmain C and catechin not only had four to eight-fold more vitamin C in the organs measured, but they were also the only group without scorbutic-type lesions. The latter finding was supported by a similar study showing fewer fresh hemorrhages in scorbutic guinea pigs receiving vitamin C with rutin or querceitin compared with vitamin C alone [66].
Several of the studies in Table 1, however, showed no differences in vitamin C accumulation in some organs (e.g., liver) [61,62,63,67]. Hughes et al. noted that the acerola cherry preparation they used was virtually flavonoid free due to dilution of the high vitamin C fruit extract, which they suggested may have accounted for its reduced efficacy compared with blackcurrant juice, which is flavonoid rich [64]. To account for the flavonoid-dependent differences in vitamin C uptake observed between the adrenals and livers of guinea pigs [62,63], Douglass and Kamp [62] noted that flavonols such as rutin are rapidly destroyed in liver tissue, but are relatively stable in adrenal homogenates. Papageorge et al. [63] also noted that when epinephrine oxidizes it can contribute to the destruction of vitamin C and thus the antioxidant effects of rutin may result in “sparing” of vitamin C in adrenals. A study by Levine’s group [54] showed that the flavonoid quercetin can reversibly inhibit vitamin C intestinal transport and decrease plasma levels of the vitamin in the CD (Sprague-Dawley) rat, although it should be noted that this is not a vitamin C deficient animal model. Some of the variability observed in these different animal studies (Table 1) may be due to the varying ratios of flavonoid to vitamin C employed.
We recently carried out a comparative bioavailability study, using the Gulo mouse model, investigating the uptake of vitamin C from kiwifruit gel compared with synthetic vitamin C [68]. We found that the kiwifruit extract, which is rich in flavonoids [69,70], provided significantly higher serum, leukocyte, heart, liver, and kidney levels of vitamin C than the purified vitamin, suggesting some type of synergistic activity of the whole fruit in this model. As with Wilson et al. [61], we did not observe any difference between the two interventions with respect to vitamin C uptake into the brain. Indeed, there is significant retention of vitamin C in the brain during dietary depletion [64,68], suggesting a vital role for vitamin C in the brain. Thus, a significant proportion of animal studies show enhanced circulating and organ levels of vitamin C in the presence of food-derived or purified flavonoids.

3. Steady State Bioavailability Studies in Humans

An early report of several patients with scurvy whose plasma vitamin C levels did not increase with synthetic vitamin C alone, but only in the form of lemon juice [45], initially leant support to the “vitamin P”/flavonoid theory. However, in contrast to the animal studies, all steady state human studies (summarized in Table 2) have shown little difference in plasma and/or urine bioavailability between synthetic vitamin C and that from different fruits, fruit juices, and vegetables [35,71,72,73,74,75,76]. Mangels et al. [35] did observe a 20% lower plasma bioavailability of vitamin C from raw broccoli compared with cooked broccoli, however, this may have been due to differences in mechanical homogenization (chewing), a similar effect to that observed for carotenoid absorption from raw versus cooked carrots.
We recently carried out a steady state bioavailability study in young non-smoking men supplemented for six weeks with 50 mg/day vitamin C, in the form of a chewable vitamin C tablet or half a gold kiwifruit [77]. This dose was chosen as it lies on the steep part of the sigmoidal plasma uptake curve [78], thus enhancing the likelihood of detecting a difference between the two interventions. Although most steady state studies have used sequential or crossover study designs, we chose a randomized parallel arms design for a number of reasons. Block et al. [79] have previously observed a lower plasma vitamin C response to supplemental vitamin C in the second phase of a multiple depletion/repletion study. Furthermore, although washout of vitamin C could be monitored between the two phases of a cross-over study, it would not be possible to monitor washout of other kiwifruit-derived components, e.g., vitamin E, which may affect the second phase of a cross-over study due to potential in vivo interactions with the supplemental vitamin C [30].
Only one previous study has investigated the comparative bioavailability of synthetic versus natural vitamin C in leukocytes [71]. These investigators found no difference in leukocyte vitamin C uptake between synthetic vitamin C (in the presence or absence of rutin) and that in orange juice two hours after a single 75 mg dose [71]. Therefore, in addition to plasma, urine, and semen samples, we also isolated peripheral blood mononuclear cells and neutrophils before and after intervention. Due to ease of accessibility and isolation, peripheral blood leukocytes are often used as a marker for tissue vitamin C status, however, whether they are a good model for all organs and tissues is uncertain. In support of this premise our animal study indicated that different organs exhibited maximal vitamin C uptake at varying doses of the vitamin [68] and we have recently shown that human skeletal muscle exhibits greater relative uptake of vitamin C than leukocytes [80]. Therefore, we also carried out needle biopsies of skeletal muscle tissue (vastus lateralis), before and after intervention. In contrast to our earlier animal study [68], our human study clearly showed no differences in the steady-state bioavailability of kiwifruit-derived versus synthetic vitamin C to plasma, semen, peripheral blood leukocytes, and skeletal muscle tissue [77]. Thus, other nutrients and phytochemicals present in kiwifruit are neither enhancing nor inhibiting the uptake of vitamin C from the whole fruit in humans.

4. Pharmacokinetic Bioavailability Studies in Humans

Pharmacokinetic studies show transient changes in plasma vitamin C levels and urinary excretion over the hours following ingestion of the vitamin C-containing test substance (relevant studies are shown in Table 3). Supplemental vitamin C typically takes about two hours to reach maximal plasma levels following ingestion. An early animal study found that vitamin C provided in citrus fruit media took longer to reach peak plasma concentrations compared with a synthetic vitamin C solution and also provided a larger area under the plasma vitamin C concentration-time curve [65]. These same investigators observed a comparable trend in human subjects supplemented with 500 mg vitamin C in the presence or absence of a citrus fruit extract [81]. The citrus fruit extract delayed maximal plasma levels by one hour and provided a 35% increase in vitamin C bioavailability. Interestingly, the citrus fruit extract increased 24 h urinary vitamin C excretion in participants pre-saturated with vitamin C, but decreased excretion in non-saturated participants compared with synthetic vitamin C alone. This suggests that the baseline vitamin C status of the individual may affect the comparative bioavailability of vitamin C. Although two other studies showed increased urinary excretion in vitamin C pre-saturated subjects in the presence of fruit juice [71,82], another pre-saturation study showed comparable plasma levels and 24 h urinary excretion in the presence of mixed bioflavonoids [83]. It should be noted that doses of 500 mg vitamin C have reduced intestinal bioavailability [78] and are significantly higher than would be obtained through a normal daily diet.
A number of pharmacokinetic studies have shown comparable bioavailability of vitamin C supplied in synthetic form or in the presence of foods or fruit juices [84,85,86,87,88]. Nelson et al. [88] used an intestinal triple lumen tube perfusion model to investigate the absorption of synthetic vitamin C and that from an orange juice solution. This method allows direct measurement of intraluminal events and showed no difference in the absorption of vitamin C from the two test solutions. A few pharmacokinetic studies have shown transient decreases in plasma vitamin C levels and/or urinary excretion at specific time points in the presence of food and fruit juices [34,71,84,85]. The physiological relevance of these transient differences is, however, likely minimal.
We recently carried out a pharmacokinetic bioavailability study of synthetic versus kiwifruit-derived vitamin C in nine non-smoking males (aged 18–35 years) who had “healthy” or “optimal” (i.e., >50 μmol/L) baseline levels of plasma vitamin C [89]. The participants received either a chewable tablet (200 mg vitamin C) or the equivalent dose from gold kiwifruit. Fasting blood and urine were collected half hourly to hourly over the eight hours following intervention. Plasma ascorbate levels increased from 0.5 h post intervention, although no significant differences in the plasma time-concentration curves were observed between the two interventions. An estimate of the total increase in plasma ascorbate indicated complete uptake of the ingested vitamin C tablet and kiwifruit-derived vitamin C. There was an increase in urinary ascorbate excretion, relative to urinary creatinine, from two hours post intervention. There was also a significant difference between the two interventions, with enhanced ascorbate excretion observed in the kiwifruit group. Urinary excretion was calculated as ~40% and ~50% of the ingested dose from the vitamin C tablet and kiwifruit arms, respectively. Overall, our pharmacokinetic study showed comparable relative bioavailability of kiwifruit-derived vitamin C and synthetic vitamin C [89].
Table
Table 1. Vitamin C comparative bioavailability studies in animal models.
Table 1. Vitamin C comparative bioavailability studies in animal models.
Animal ModelInterventionStudy DesignVitamin C AnalysisBioavailability Findings: Natural vs. Synthetic Vitamin CBioavailability Summary: Natural vs. Synthetic Vitamin CReference
Gulo−/− mice0.5–5 mg/day vitamin C solution 4 weeks interventionHPLC-ECDKiwifruit ↑ serum, leukocyte, heart, liver, and kidney, but not brain vitamin CEnhanced uptake in 5/6 pools[68]
Kiwifruit gel
CD rats60 mg/kg vitamin C gavageSingle dose; 4 h samplingHPLC-ECDQuercetin ↓ plasma vitamin C (at 4 h)Decreased uptake in 1/1 pool[54]
15 mg/kg quercetin
Guinea pigs50 mg vitamin C solutionSingle dose; 4 h samplingFluorometric (NQSA)Citrus fruit media ↑ plasma AUCEnhanced uptake in 1/1 pool[65]
Citrus fruit media
1 mg/kg vitamin C (low vitamin C diet)26 days interventionColorimetric (DCPIP)Orange peel extract ↑ adrenal, spleen and leukocyte, but not brain vitamin C; hesperidin ↑ adrenal and leukocyte, but not spleen vitamin CEnhanced uptake in 3/4 pools[61]
50 mg/kg orange peel extract
50 mg/kg hesperidin
5 mg/kg vitamin C solution23 days interventionColorimetric (DCPIP)Black current juice ↑ adrenal and spleen vitamin C; acerola cherry juice comparable adrenal and spleen vitamin CEnhanced uptake in 2/2 organs[64]
Black current juice
Acerola cherry juice
0, 5 and 10 mg/kg vitamin C3 weeks interventionColorimetric (DNPH)Rutin ↑ adrenal, but not liver vitamin CEnhanced uptake in 1/2 pools[62]
50 mg rutin
4 mg/kg vitamin C (low vitamin C diet)22 days interventionColorimetric (DNPH)Rutin ↑ adrenal, but not liver or whole blood vitamin C of adequate animalsEnhanced uptake in 1/3 pools[63]
10 mg rutin tablet
18 mg/kg vitamin C (adequate vitamin C diet)
10 mg rutin tablet
Basic diet23 days interventionColorimetric (DCPIP)Vitamin C + catechin ↑ liver, spleen, kidney, and adrenal vitamin CEnhanced uptake in 4/4 organs[42]
1 mg/animal catechin
10 mg/animal vitamin C
Vitamin C + catechin
0.5 mg/day vitamin C solution 20 days interventionColorimetric (DCPIP)Lemon juice comparable plasma and adrenal vitamin C Comparable uptake in 2/2 pools[67]
1 mL lemon juice
NQSA: 1,2-naphthoquinone-4-sulfonic acid; AUC: area under the concentration-time curve; DNPH: 2,4-dinitrophenylhydrazine; DCPIP: 2,6-dichlorophenolindophenol.
Table
Table 2. Steady state comparative bioavailability studies in humans.
Table 2. Steady state comparative bioavailability studies in humans.
SubjectsInterventionStudy DesignVitamin C AnalysisBioavailability Findings: Natural vs. Synthetic Vitamin CBioavailability Summary: Natural vs. Synthetic Vitamin CReference
36 non-smoking males 18–35 years50 mg/day vitamin C tablet6 weeks of supplementation; Parallel designHPLC-ECDKiwifruit comparable plasma, urine, semen, mononuclear cell, neutrophil and muscle tissue vitamin CComparable uptake in 6/6 pools[77]
Gold kiwifruit (50 mg vitamin C)
11 non-smoking women 21–39 years69 mg/day vitamin C capsule2 weeks of supplementation; Crossover design (2 week washout)Colorimetric (DNPH)Orange juice comparable plasma vitamin CComparable uptake in 1/1 pool[76]
Orange juice (66 mg vitamin C)
68 non-smoking males 30–59 years108 mg/day vitamin C tablet4 weeks of supplementation; Crossover design (4 week washout)Colorimetric (DNPH)Orange pieces/juice or cooked broccoli comparable plasma vitamin C; raw broccoli ↓ plasma vitamin CComparable uptake in 1/1 pool[35]
Orange—pieces or juice
Broccoli—cooked or raw
14 men and women75 mg/day vitamin CSequential designColorimetricPapayas and guava juice comparable plasma and urinary vitamin CComparable uptake in 2/2 pools[72]
Papayas (75 mg/day vitamin C)
Guava juice (75 mg/day vitamin C)
4 healthy young subjects75 mg/day vitamin C tabletsPre-study saturation; Sequential designColorimetricRaw cabbage and tomato juice comparable plasma and urinary vitamin CComparable uptake in 2/2 pools[73]
Raw cabbage (75 mg/day vitamin C)
Tomato juice (75 mg/day vitamin C)
7 college women40 mg/day vitamin C solutionPre-study saturation; Sequential designColorimetric (DCPIP)Raspberries comparable blood and urinary vitamin CComparable uptake in 2/2 pools[74]
Red raspberries (40 mg/day vitamin C)
12 young adults100 mg/day vitamin CSequential designColorimetric (DCPIP)Orange juice comparable urinary vitamin C Comparable uptake in 1/1 pool[75]
Orange juice (100 mg/day vitamin C)
DNPH: 2,4-dinitrophenylhydrazine; DCPIP: 2,6-dichlorophenolindophenol.
Table
Table 3. Pharmacokinetic comparative bioavailability studies in humans.
Table 3. Pharmacokinetic comparative bioavailability studies in humans.
SubjectsInterventionStudy DesignVitamin C AnalysisPlasma UptakeUrinary ExcretionReference
9 non-smoking males 18–35 years200 mg vitamin C tablet8 h sampling; Crossover design (3 week washout)HPLC-ECDKiwifruit comparable plasma vitamin C and AUCKiwifruit ↑ urinary vitamin C and AUC (relative to creatinine)[89]
Gold kiwifruit (200 mg vitamin C)
5 non-smoking males 22–27 years50 mg vitamin C solution;8 h sampling; Crossover design (4 week washout)HPLC-ECDMashed potatoes ↓ plasma vitamin C (at 1 to 2.5 h); potato chips ↓ AUCMashed potatoes ↓ urinary vitamin C (at 3 h)[84]
282 g mashed potato (50 mg vitamin C)
87 g potato chips (50 mg vitamin C)
Placebo
5 non-smoking males 22–26 years50–500 mg vitamin C solution 6 h sampling; Crossover designHPLC-ECDAcerola juice comparable plasma vitamin C and AUCAcerola juice ↓ urinary vitamin C (at 1, 2 and 5 h)[85]
100 mL acerola juice (50 mg vitamin C)
12 males 20–35 years284 mg vitamin C drink4.5 h sampling; Crossover design (1 week washout)Colorimetric (TPTZ)Orange juice comparable bioavailability (AUC/concentration)ND[86]
590 mL orange juice (68 mg vitamin C)
Placebo (milk)
7 non-smoking females150 mg vitamin C solution8 h sampling; Crossover design (2 week washout)HPLC-UVOrange juice comparable plasma vitamin CND[87]
300 mL orange juice (150 mg vitamin C)
Placebo
7 non-smokers 26–59 years30 mg vitamin C solution4 h sampling; Crossover design (3–4 week washout)Fluorometric (phenylene diamine)Grape juice ↓ plasma vitamin C (at 16 to 28 min)ND[34]
200 mL red grape juice (30 mg vitamin C)
9 healthy subjects 19–41 years500 mg vitamin C tablet1 g/day vitamin C for 2 weeks pre-study; 8 h sampling; Crossover design (1 week washout)Colorimetric (DNPH)Bioflavonoids comparable AUCBioflavonoids comparable 24 h vitamin C excretion[83]
Mixed bioflavonoids
Placebo
12 non-smoking subjects 18–41 years500 mg vitamin C solutionSubgroup had 1 g/day vitamin C for 2 weeks pre-study; 8 h sampling; Crossover design (1 week washout)FluorometricCitrus extract ↑ AUCCitrus extract ↓ 24 h vitamin C excretion in non-saturated subjects and ↑ 24 h vitamin C excretion in saturated subjects [81]
2 g citrus extract
Placebo
5 men 21–25 years500 mg vitamin C solution100 mg/day vitamin C for 1 month pre-study; 8 h sampling; Crossover design (1 week washout)Colorimetric (Indophenol dye)NDBlackcurrant juice slight ↑ 8 h vitamin C excretion in saturated subjects[82]
500 mg vitamin C in blackcurrant juice
15 normal subjects (4 smokers) 20–42 years70 mg/h vitamin C solutionIntestinal perfusion; Tandem designColorimetric (DNPH)Orange juice comparable intestinal absorptionND[88]
Orange juice
12 men (6 smokers) 23–44 years75 mg vitamin C solution Pre- and post-saturation with 1 mg/day vitamin C; 2–24 h sampling; Crossover design (1 day washout)ColorimetricOrange juice and rutin ↓ plasma vitamin C (at 2 h)Orange juice slight ↑ 24 h vitamin C excretion[71]
400 mg rutin
Orange juice (75 mg vitamin C)
AUC: area under the concentration-time curve; ND: not determined; DNPH: 2,4-dinitrophenylhydrazine; TPTZ: 2,4,6-tris(2-pyridyl)-s-triazine.

5. Vitamin C Bioavailability from Different Tablet Formulations

Doses of vitamin C up to 2000 mg/day are considered safe for general consumption [90]. However, pharmacokinetic studies indicate that ingestion of single doses of vitamin C greater than 200 mg have lower relative bioavailability [78], indicating that ingestion of several smaller doses each day is preferable to a single large dose. A number of studies have investigated the relative bioavailability of vitamin C from different tablet formulations and have shown that slow-release formulations provide superior vitamin bioavailability [91,92,93,94]. Salts of vitamin C, such as sodium and calcium ascorbate (Ester-C), have also been tested. Animal studies indicated that Ester-C (which contains calcium ascorbate, as well as DHA and calcium threonate) was absorbed more readily and excreted less rapidly than ascorbic acid [95] and had superior anti-scorbutic activity in ODS rats [96]. Johnston and Luo [83], however, found no significant differences between Ester-C and ascorbic acid bioavailability in humans. Nevertheless, Ester-C has been shown to be better tolerated in individuals sensitive to acidic foods [97].

6. Conclusions

Overall, a majority of animal studies have shown differences in the comparative bioavailability of synthetic versus food-derived vitamin C, or vitamin C in the presence of isolated bioflavonoids, although the results varied depending on the animal model, study design and body compartments measured. In contrast, all steady state comparative bioavailability studies in humans have shown no differences between synthetic and natural vitamin C, regardless of the subject population, study design or intervention used. Some pharmacokinetic studies in humans have shown transient and small comparative differences between synthetic and natural vitamin C, although these differences are likely to have minimal physiological impact. Thus, not only do the reviewed studies reiterate the injunction that the findings of animal studies should not be directly translated to humans [98,99], but it is also apparent that additional comparative bioavailability studies in humans are unwarranted.
Although synthetic and food-derived vitamin C appear to be equally bioavailable in humans, ingesting vitamin C as part of a whole food is considered preferable because of the concomitant consumption of numerous other macro- and micronutrients and phytochemicals, which will confer additional health benefits. Numerous epidemiological studies have indicated that higher intakes of fruit and vegetables are associated with decreased incidence of stroke [100], coronary heart disease [101], and cancers at various sites [102,103]. Vitamin C status is one of the best markers for fruit and vegetable intake [104], and food-derived vitamin C is associated with decreased incidence of numerous chronic diseases [1], however, whether the observed health effects of fruit and vegetable ingestion are due to vitamin C and/or other plant-derived components is currently unknown. With respect to coronary heart disease, strong evidence exists for a protective effect of vegetables, moderate evidence for fruit and dietary vitamin C and insufficient evidence for supplemental vitamin C [105]. Some meta-analyses support the premise that dietary vitamin C is more protective than supplements [106], while others show reduced disease incidence with supplemental but not dietary vitamin C [107].
A major limitation with epidemiological studies is that they show only an association between dietary vitamin C intake and disease risk and cannot ascertain whether different sources of vitamin C (i.e., food-derived versus supplement) are a cause, consequence, or simply a correlate of the particular end-point measured. Interpretations can also vary significantly depending on the input of different confounders [108]. Furthermore, epidemiological studies rely predominantly on food frequency questionnaires [109,110] and 24 h dietary recalls [111] to ascertain vitamin C intakes from foods and/or supplements [112]. This methodology has numerous limitations [113] and correlations with vitamin C status can vary depending on the methods employed as well as numerous other external factors [114]. Pooled or meta-analyses of epidemiological studies are particularly problematic due to the combining of variable study designs, cohorts and endpoints, often resulting in dilution or misinterpretation of study findings.
The gold standard for determining causality is the double-blind randomized placebo controlled clinical trial. Although this type of study design works well for comparing the effects of drugs against a placebo, it does not work for nutrients, such as vitamin C, which are already in the food chain and are required for life, i.e., there is no true placebo. Numerous other methodological issues have been identified with the design of many clinical trials investigating the health effects of vitamin C [115]. For example, a major flaw with many vitamin C intervention studies is the use of study populations with already adequate or even saturating vitamin C levels, which significantly decreases the likelihood of observing any effects of the intervention. Thus, it is recommended that study populations are comprised of individuals with sub-optimal vitamin C status (i.e., <50 μmol/L plasma vitamin C) or that sub-group analysis is carried out on the low vitamin C sub-populations [116]. With pharmacokinetic studies, both unsaturated and saturated individuals can be used, but comparative bioavailability studies have shown that results may vary depending on the baseline vitamin C status of the study subjects. Furthermore, the vitamin C doses chosen for intervention are critical since doses above 200 mg have decreased intestinal uptake [78], indicating that if higher doses are warranted then these should be provided as multiple doses of ~200 mg each to ensure complete bioavailability.
The comparative health effects of supplemental versus food-derived vitamin C will only be determined through the use of appropriate and well-designed studies. Determination of the physiological effects or health outcomes of intervention with synthetic versus natural vitamin C will depend largely on the endpoints measured. Only a handful of comparative intervention studies have been carried out to assess specific physiological or health endpoints. Guarnieri et al. [89] investigated potential protection of mononuclear leukocytes from supplemented individuals against ex vivo oxidative DNA damage. Although they found comparable vitamin C bioavailability between a single portion of orange juice (containing 150 mg vitamin C) and a synthetic vitamin C drink of the same dosage, they showed that only the orange juice protected the leukocytes from ex vivo oxidative DNA damage [89]. However, how closely ex vivo oxidation of DNA resembles events occurring in vivo is debatable and results could also vary significantly depending on the type of oxidative stress. Johnston et al. [76] compared plasma lipid peroxidation in individuals who had been supplemented with either orange juice or synthetic vitamin C (~70 mg/day) for two weeks. They found comparable vitamin C bioavailability and a similar reduction in lipid peroxidation with both interventions [76]. Several studies have assessed the effects of synthetic and natural vitamin C, or vitamin C in the presence of bioflavonoids, on the common cold. Two earlier studies showed a lack of an effect of vitamin C (~200 mg/day), with and without purified bioflavonoids, on the prevention and cure of the common cold [117,118]. Another study indicated that synthetic vitamin C (80 mg/day) and orange juice both decreased the symptoms of the common cold compared with placebo, but there were no differences between the two interventions [119].
As alluded to in the introduction, vitamin C is known to enhance the bioavailability of other nutrients, such as vitamin E [30] and non-heme iron [31,32], which may enhance the health effects of vitamin C-containing foods. Bioflavonoids are also known to have numerous biological activities [120]. Recently vitamin C has been shown to modulate specific biological activities of quercetin and tea polyphenols [121,122]. Thus, future studies may elucidate the physiological relevance of these interactions.

Conflicts of Interest

The authors declare no conflict of interest.

Acknowledgments

Co-funding was provided by the New Zealand Ministry of Business, Innovation & Employment and Zespri International Ltd., Mount Maunganui, New Zealand.

References

  1. Carr, A.C.; Frei, B. Toward a new recommended dietary allowance for vitamin C based on antioxidant and health effects in humans. Am. J. Clin. Nutr. 1999, 69, 1086–1107. [Google Scholar]
  2. Englard, S.; Seifter, S. The biochemical functions of ascorbic acid. Annu. Rev. Nutr. 1986, 6, 365–406. [Google Scholar]
  3. Ozer, A.; Bruick, R.K. Non-heme dioxygenases: Cellular sensors and regulators jelly rolled into one? Nat. Chem. Biol. 2007, 3, 144–153. [Google Scholar] [CrossRef]
  4. Monfort, A.; Wutz, A. Breathing-in epigenetic change with vitamin C. EMBO Rep. 2013, 14, 337–346. [Google Scholar]
  5. Hornig, D. Distribution of ascorbic acid, metabolites and analogues in man and animals. Ann. N. Y. Acad. Sci. 1975, 258, 103–118. [Google Scholar]
  6. Omaye, S.T.; Schaus, E.E.; Kutnink, M.A.; Hawkes, W.C. Measurement of vitamin C in blood components by high-performance liquid chromatography. Implication in assessing vitamin C status. Ann. N. Y. Acad. Sci. 1987, 498, 389–401. [Google Scholar]
  7. Tsao, C.S. An Overview of Ascorbic Acid Chemistry and Biochemistry. In Vitamin C in Health and Disease; Packer, L., Fuchs, J., Eds.; Marcel Dekker: New York, NY, USA, 1997; pp. 25–58. [Google Scholar]
  8. Nishikimi, M.; Fukuyama, R.; Minoshima, S.; Shimizu, N.; Yagi, K. Cloning and chromosomal mapping of the human nonfunctional gene for l-gulono-γ-lactone oxidase, the enzyme for l-ascorbic acid biosynthesis missing in man. J. Biol. Chem. 1994, 269, 13685–13688. [Google Scholar]
  9. Krebs, H.A. The Sheffield Experiment on the vitamin C requirement of human adults. Proc. Nutr. Soc. 1953, 12, 237–246. [Google Scholar]
  10. Sauberlich, H.E. A History of Scurvy and Vitamin C. In Vitamin C in Health and Disease; Packer, L., Fuchs, J., Eds.; Marcel Dekker: New York, NY, USA, 1997; pp. 1–24. [Google Scholar]
  11. Michels, A.J.; Hagen, T.M.; Frei, B. Human genetic variation influences vitamin C homeostasis by altering vitamin C transport and antioxidant enzyme function. Annu. Rev. Nutr. 2013, 33, 45–70. [Google Scholar]
  12. Tsukaguchi, H.; Tokui, T.; Mackenzie, B.; Berger, U.V.; Chen, X.Z.; Wang, Y.; Brubaker, R.F.; Hediger, M.A. A family of mammalian Na+-dependent l-ascorbic acid transporters. Nature 1999, 399, 70–75. [Google Scholar]
  13. Savini, I.; Rossi, A.; Pierro, C.; Avigliano, L.; Catani, M.V. SVCT1 and SVCT2: Key proteins for vitamin C uptake. Amino Acids 2008, 34, 347–355. [Google Scholar]
  14. Rumsey, S.C.; Welch, R.W.; Garraffo, H.M.; Ge, P.; Lu, S.F.; Crossman, A.T.; Kirk, K.L.; Levine, M. Specificity of ascorbate analogs for ascorbate transport. Synthesis and detection of [(125)I]6-deoxy-6-iodo-l-ascorbic acid and characterization of its ascorbate-specific transport properties. J. Biol. Chem. 1999, 274, 23215–23222. [Google Scholar]
  15. Goldman, H.M.; Gould, B.S.; Munro, H.N. The antiscorbutic action of l-ascorbic acid and d-isoascorbic acid (erythorbic acid) in the guinea pig. Am. J. Clin. Nutr. 1981, 34, 24–33. [Google Scholar]
  16. Hughes, R.E.; Hurley, R.J. The uptake of d-araboascorbic acid (d-isoascorbic acid) by guinea-pig tissues. Br. J. Nutr. 1969, 23, 211–216. [Google Scholar]
  17. Levine, M. Fruits and vegetables: There is no substitute. Am. J. Clin. Nutr. 1996, 64, 381–382. [Google Scholar]
  18. Sauberlich, H.E.; Tamura, T.; Craig, C.B.; Freeberg, L.E.; Liu, T. Effects of erythorbic acid on vitamin C metabolism in young women. Am. J. Clin. Nutr. 1996, 64, 336–346. [Google Scholar]
  19. Corpe, C.P.; Eck, P.; Wang, J.; Al-Hasani, H.; Levine, M. Intestinal dehydroascorbic acid (DHA) transport mediated by the facilitative sugar transporters, GLUT2 and GLUT8. J. Biol. Chem. 2013, 288, 9092–9101. [Google Scholar]
  20. Rumsey, S.C.; Kwon, O.; Xu, G.W.; Burant, C.F.; Simpson, I.; Levine, M. Glucose transporter isoforms GLUT1 and GLUT3 transport dehydroascorbic acid. J. Biol. Chem. 1997, 272, 18982–18989. [Google Scholar]
  21. Vera, J.C.; Rivas, C.I.; Fischbarg, J.; Golde, D.W. Mammalian facilitative hexose transporters mediate the transport of dehydroascorbic acid. Nature 1993, 364, 79–82. [Google Scholar]
  22. Washko, P.W.; Wang, Y.; Levine, M. Ascorbic acid recycling in human neutrophils. J. Biol. Chem. 1993, 268, 15531–15535. [Google Scholar]
  23. Corti, A.; Casini, A.F.; Pompella, A. Cellular pathways for transport and efflux of ascorbate and dehydroascorbate. Arch. Biochem. Biophys. 2010, 500, 107–115. [Google Scholar]
  24. Nishiyama, I.; Yamashita, Y.; Yamanaka, M.; Shimohashi, A.; Fukuda, T.; Oota, T. Varietal difference in vitamin C content in the fruit of kiwifruit and other actinidia species. J. Agric. Food Chem. 2004, 52, 5472–5475. [Google Scholar]
  25. Dhariwal, K.R.; Hartzell, W.O.; Levine, M. Ascorbic acid and dehydroascorbic acid measurements in human plasma and serum. Am. J. Clin. Nutr. 1991, 54, 712–716. [Google Scholar]
  26. Ogiri, Y.; Sun, F.; Hayami, S.; Fujimura, A.; Yamamoto, K.; Yaita, M.; Kojo, S. Very low vitamin C activity of orally administered l-dehydroascorbic acid. J. Agric. Food Chem. 2002, 50, 227–229. [Google Scholar]
  27. Welch, R.W.; Wang, Y.; Crossman, A., Jr.; Park, J.B.; Kirk, K.L.; Levine, M. Accumulation of vitamin C (ascorbate) and its oxidized metabolite dehydroascorbic acid occurs by separate mechanisms. J. Biol. Chem. 1995, 270, 12584–12592. [Google Scholar]
  28. Wang, Y.; Russo, T.A.; Kwon, O.; Chanock, S.; Rumsey, S.C.; Levine, M. Ascorbate recycling in human neutrophils: Induction by bacteria. Proc. Natl. Acad. Sci. USA 1997, 94, 13816–13819. [Google Scholar]
  29. Packer, J.E.; Slater, T.F.; Willson, R.L. Direct observation of a free radical interaction between vitamin E and vitamin C. Nature 1979, 278, 737–738. [Google Scholar]
  30. Tanaka, K.; Hashimoto, T.; Tokumaru, S.; Iguchi, H.; Kojo, S. Interactions between vitamin C and vitamin E are observed in tissues of inherently scorbutic rats. J. Nutr. 1997, 127, 2060–2064. [Google Scholar]
  31. Beck, K.; Conlon, C.A.; Kruger, R.; Coad, J.; Stonehouse, W. Gold kiwifruit consumed with an iron-fortified breakfast cereal meal improves iron status in women with low iron stores: A 16-week randomised controlled trial. Br. J. Nutr. 2011, 105, 101–109. [Google Scholar]
  32. Hallberg, L.; Brune, M.; Rossander, L. Effect of ascorbic acid on iron absorption from different types of meals. Studies with ascorbic-acid-rich foods and synthetic ascorbic acid given in different amounts with different meals. Hum. Nutr. Appl. Nutr. 1986, 40, 97–113. [Google Scholar]
  33. Scheers, N.M.; Sandberg, A.S. Iron regulates the uptake of ascorbic acid and the expression of sodium-dependent vitamin C transporter 1 (SVCT1) in human intestinal Caco-2 cells. Br. J. Nutr. 2011, 105, 1734–1740. [Google Scholar]
  34. Bates, C.J.; Jones, K.S.; Bluck, L.J. Stable isotope-labelled vitamin C as a probe for vitamin C absorption by human subjects. Br. J. Nutr. 2004, 91, 699–705. [Google Scholar]
  35. Mangels, A.R.; Block, G.; Frey, C.M.; Patterson, B.H.; Taylor, P.R.; Norkus, E.P.; Levander, O.A. The bioavailability to humans of ascorbic acid from oranges, orange juice and cooked broccoli is similar to that of synthetic ascorbic acid. J. Nutr. 1993, 123, 1054–1061. [Google Scholar]
  36. Keltz, F.R.; Kies, C.; Fox, H.M. Urinary ascorbic acid excretion in the human as affected by dietary fiber and zinc. Am. J. Clin. Nutr. 1978, 31, 1167–1171. [Google Scholar]
  37. Rusznyak, S.; Szent-Gyorgyi, A. Vitamin P: Flavonols as vitamins. Nature 1936, 138, 27. [Google Scholar]
  38. Bentsath, A.; Rusznyak, S.; Szent-Gyorgyi, A. Vitamin nature of flavones. Nature 1936, 138, 798. [Google Scholar]
  39. Bentsath, A.; Rusznyak, S.; Szent-Gyorgyi, A. Vitamin P. Nature 1937, 139, 326–327. [Google Scholar]
  40. Rusznyak, S.; Benko, A. Experimental vitamin P deficiency. Science 1941, 94, 25. [Google Scholar]
  41. Zilva, S.S. Vitamin P. Biochem. J. 1937, 31, 915–919. [Google Scholar]
  42. Cotereau, H.; Gabe, M.; Géro, E.; Parrot, J.-L. Influence of vitamin P (vitamin C2) upon the amount of ascorbic acid in the organs of the guinea pig. Nature 1948, 161, 557. [Google Scholar]
  43. Scarborough, H. Deficiency of vitamin C and vitamin P in man. Lancet 1940, 236, 644–647. [Google Scholar]
  44. Scarborough, H. Vitamin P. Biochem. J. 1939, 33, 1400–1407. [Google Scholar]
  45. Elmby, A.; Warburg, E. The inadequacy of synthetic ascorbic acid as an antiscorbutic agent. Lancet 1937, 230, 1363–1365. [Google Scholar]
  46. Ivanov, V.; Carr, A.C.; Frei, B. Red wine antioxidants bind to human lipoproteins and protect them from metal ion-dependent and -independent oxidation. J. Agric. Food Chem. 2001, 49, 4442–4449. [Google Scholar]
  47. Bors, W.; Michel, C.; Saran, M. Flavonoid antioxidants: rate constants for reactions with oxygen radicals. Methods Enzymol. 1994, 234, 420–429. [Google Scholar] [CrossRef]
  48. Beker, B.Y.; Sonmezoglu, I.; Imer, F.; Apak, R. Protection of ascorbic acid from copper(II)-catalyzed oxidative degradation in the presence of flavonoids: Quercetin, catechin and morin. Int. J. Food Sci. Nutr. 2011, 62, 504–512. [Google Scholar]
  49. Clemetson, C.A.; Andersen, L. Plant polyphenols as antioxidants for ascorbic acid. Ann. N. Y. Acad Sci. 1966, 136, 341–376. [Google Scholar] [CrossRef]
  50. Harper, K.A.; Morton, A.D.; Rolfe, E.J. The phenolic compounds of blackcurrant juice and their protective effect on ascorbic acid III. The mechansim of ascorbic acid oxidation and its inhibition by flavonoids. Int. J. Food Sci. Technol. 1969, 4, 255–267. [Google Scholar]
  51. Clegg, K.M.; Morton, A.D. The phenolic compounds of blackcurrant juice and their protective effect on ascorbic acid II. The stability of ascorbic acid in model systems containing some of the phenolic compounds associated with blackcurrant juice. Int. J. Food Sci. Technol. 1968, 3, 277–284. [Google Scholar]
  52. Carr, A.; Frei, B. Does vitamin C act as a pro-oxidant under physiological conditions? FASEB J. 1999, 13, 1007–1024. [Google Scholar]
  53. Lotito, S.B.; Frei, B. Consumption of flavonoid-rich foods and increased plasma antioxidant capacity in humans: Cause, consequence, or epiphenomenon? Free Radi. Biol. Med. 2006, 41, 1727–1746. [Google Scholar]
  54. Song, J.; Kwon, O.; Chen, S.; Daruwala, R.; Eck, P.; Park, J.B.; Levine, M. Flavonoid inhibition of sodium-dependent vitamin C transporter 1 (SVCT1) and glucose transporter isoform 2 (GLUT2), intestinal transporters for vitamin C and Glucose. J. Biol. Chem. 2002, 277, 15252–15260. [Google Scholar]
  55. Park, J.B.; Levine, M. Intracellular accumulation of ascorbic acid is inhibited by flavonoids via blocking of dehydroascorbic acid and ascorbic acid uptakes in HL-60, U937 and Jurkat cells. J. Nutr. 2000, 130, 1297–1302. [Google Scholar]
  56. Corpe, C.P.; Lee, J.H.; Kwon, O.; Eck, P.; Narayanan, J.; Kirk, K.L.; Levine, M. 6-Bromo-6-deoxy-l-ascorbic acid: An ascorbate analog specific for Na+-dependent vitamin C transporter but not glucose transporter pathways. J. Biol. Chem. 2005, 280, 5211–5220. [Google Scholar]
  57. Washko, P.W.; Welch, R.W.; Dhariwal, K.R.; Wang, Y.; Levine, M. Ascorbic acid and dehydroascorbic acid analyses in biological samples. Anal. Biochem. 1992, 204, 1–14. [Google Scholar]
  58. Mizushima, Y.; Harauchi, T.; Yoshizaki, T.; Makino, S. A rat mutant unable to synthesize vitamin C. Experientia 1984, 40, 359–361. [Google Scholar]
  59. Maeda, N.; Hagihara, H.; Nakata, Y.; Hiller, S.; Wilder, J.; Reddick, R. Aortic wall damage in mice unable to synthesize ascorbic acid. Proc. Natl. Acad. Sci. USA 2000, 97, 841–846. [Google Scholar]
  60. Mohan, S.; Kapoor, A.; Singgih, A.; Zhang, Z.; Taylor, T.; Yu, H.; Chadwick, R.B.; Chung, Y.S.; Donahue, L.R.; Rosen, C.; et al. Spontaneous fractures in the mouse mutant sfx are caused by deletion of the gulonolactone oxidase gene, causing vitamin C deficiency. J. Bone Miner. Res. 2005, 20, 1597–1610. [Google Scholar]
  61. Wilson, H.K.; Price-Jones, C.; Hughes, R.E. The influence of an extract of orange peel on the growth and ascorbic acid metabolism of young guinea-pigs. J. Sci. Food Agric. 1976, 27, 661–666. [Google Scholar]
  62. Douglass, C.D.; Kamp, G.H. The effect of orally administered rutin on the adrenal ascorbic acid level in guinea pigs. J. Nutr. 1959, 67, 531–536. [Google Scholar]
  63. Papageorge, E.; Mitchell, G.L., Jr. The effect of oral administration of rutin on blood, liver and adrenal ascorbic acid and on liver and adrenal cholesterol in guinea pigs. J. Nutr. 1949, 37, 531–540. [Google Scholar]
  64. Hughes, R.E.; Hurley, R.J.; Jones, P.R. The retention of ascorbic acid by guinea-pig tissues. Br. J. Nutr. 1971, 26, 433–438. [Google Scholar] [CrossRef]
  65. Vinson, J.A.; Bose, P. Comparative bioavailability of synthetic and natural vitamin C in guinea pigs. Nutr. Rep. Int. 1983, 27, 875–879. [Google Scholar]
  66. Ambrose, A.M.; De, E.F. The value of rutin and quercetin in scurvy. J. Nutr. 1949, 38, 305–317. [Google Scholar]
  67. Todhunter, E.N.; Robbins, R.C.; Ivey, G.; Brewer, W. A comparison of the utilization by guinea pigs of equivalent amounts of ascorbic acid (vitamin C) in lemon juice and in crystalline form. J. Nutr. 1940, 19, 113–120. [Google Scholar]
  68. Vissers, M.C.M.; Bozonet, S.M.; Pearson, J.F.; Braithwaite, L.J. Dietary ascorbate affects steady state tissue levels in vitamin C-deficient mice: Tissue deficiency after sub-optimal intake and superior bioavailability from a food source (kiwifruit). Am. J. Clin. Nutr. 2011, 93, 292–301. [Google Scholar]
  69. Latocha, P.; Krupa, T.; Wolosiak, R.; Worobiej, E.; Wilczak, J. Antioxidant activity and chemical difference in fruit of different Actinidia sp. Int J. Food Sci. Nutr. 2010, 61, 381–394. [Google Scholar]
  70. Fiorentino, A.; D’Abrosca, B.; Pacifico, S.; Mastellone, C.; Scognamiglio, M.; Monaco, P. Identification and assessment of antioxidant capacity of phytochemicals from kiwi fruits. J. Agric. Food Chem. 2009, 57, 4148–4155. [Google Scholar]
  71. Pelletier, O.; Keith, M.O. Bioavailability of synthetic and natural ascorbic acid. J. Am. Diet. Assoc. 1974, 64, 271–275. [Google Scholar]
  72. Hartzler, E.R. The availability of ascorbic acid in papayas and guavas. J. Nutr. 1945, 30, 355–365. [Google Scholar]
  73. Clayton, M.M.; Borden, R.A. The availability for human nutrition of the vitamin C in raw cabbage and home-canned tomato juice. J. Nutr. 1943, 25, 349–369. [Google Scholar]
  74. Todhunter, E.N.; Fatzer, A.S. A comparison of the utilization by college women of equivalent amounts of ascorbic acid (vitamin C) in red raspberries and in crystalline form. J. Nutr. 1940, 19, 121–130. [Google Scholar]
  75. Hawley, E.E.; Stephens, D.J.; Anderson, G. The excretion of vitamin C in normal individuals following a comparable quantitative administration in the form of orange juice, cevitamic acid by mouth and cevitamic acid intravenously. J. Nutr. 1936, 11, 135–145. [Google Scholar]
  76. Johnston, C.S.; Dancho, C.L.; Strong, G.M. Orange juice ingestion and supplemental vitamin C are equally effective at reducing plasma lipid peroxidation in healthy adult women. J. Am. Coll. Nutr. 2003, 22, 519–523. [Google Scholar]
  77. Carr, A.C.; Bozonet, S.M.; Pullar, J.M.; Simcock, J.W.; Vissers, M.C. A randomised steady-state bioavailability study of synthetic and natural (kiwifruit-derived) vitamin C. Nutrients 2013, 5, 3684–3695. [Google Scholar]
  78. Levine, M.; Conry-Cantilena, C.; Wang, Y.; Welch, R.W.; Washko, P.W.; Dhariwal, K.R.; Park, J.B.; Lazarev, A.; Graumlich, J.F.; King, J.; et al. Vitamin C pharmacokinetics in healthy volunteers: Evidence for a recommended dietary allowance. Proc. Natl. Acad. Sci. USA 1996, 93, 3704–3709. [Google Scholar]
  79. Block, G.; Mangels, A.R.; Patterson, B.H.; Levander, O.A.; Norkus, E.P.; Taylor, P.R. Body weight and prior depletion affect plasma ascorbate levels attained on identical vitamin C intake: A controlled-diet study. J. Am. Coll. Nutr. 1999, 18, 628–637. [Google Scholar]
  80. Carr, A.C.; Bozonet, S.M.; Pullar, J.M.; Simcock, J.W.; Vissers, M.C. Human skeletal muscle ascorbate is highly responsive to changes in vitamin C intake and plasma concentrations. Am. J. Clin. Nutr. 2013, 97, 800–807. [Google Scholar]
  81. Vinson, J.A.; Bose, P. Comparative bioavailability to humans of ascorbic acid alone or in a citrus extract. Am. J. Clin. Nutr. 1988, 48, 601–604. [Google Scholar]
  82. Jones, E.; Hughes, R.E. The influence of bioflavonoids on the absorption of vitamin C. IRCS J. Med. Sci. 1984, 12, 320. [Google Scholar]
  83. Johnston, C.S.; Luo, B. Comparison of the absorption and excretion of three commercially available sources of vitamin C. J. Am. Diet. Assoc. 1994, 94, 779–781. [Google Scholar]
  84. Kondo, Y.; Higashi, C.; Iwama, M.; Ishihara, K.; Handa, S.; Mugita, H.; Maruyama, N.; Koga, H.; Ishigami, A. Bioavailability of vitamin C from mashed potatoes and potato chips after oral administration in healthy Japanese men. Br. J. Nutr. 2012, 107, 885–892. [Google Scholar]
  85. Uchida, E.; Kondo, Y.; Amano, A.; Aizawa, S.; Hanamura, T.; Aoki, H.; Nagamine, K.; Koizumi, T.; Maruyama, N.; Ishigami, A. Absorption and excretion of ascorbic acid alone and in acerola (Malpighia emarginata) juice: Comparison in healthy japanese subjects. Biol. Pharm. Bull. 2011, 34, 1744–1747. [Google Scholar]
  86. Carter, B.; Monsivais, P.; Drewnowski, A. Absorption of folic acid and ascorbic acid from nutrient comparable beverages. J. Food Sci. 2010, 75, H289–H293. [Google Scholar]
  87. Guarnieri, S.; Riso, P.; Porrini, M. Orange juice vs vitamin C: Effect on hydrogen peroxide-induced DNA damage in mononuclear blood cells. Br. J. Nutr. 2007, 97, 639–643. [Google Scholar]
  88. Nelson, E.W.; Streiff, R.R.; Cerda, J.J. Comparative bioavailability of folate and vitamin C from a synthetic and a natural source. Am. J. Clin. Nutr. 1975, 28, 1014–1019. [Google Scholar]
  89. Carr, A.C.; Bozonet, S.M.; Vissers, M.C.M. A randomised cross-over pharmacokinetic bioavailabiltiy study of synthetic versus kiwifruit-derived vitamin C. Nutrients 2013, 5, 3684–3695. [Google Scholar]
  90. Hathcock, J.N.; Azzi, A.; Blumberg, J.; Bray, T.; Dickinson, A.; Frei, B.; Jialal, I.; Johnston, C.S.; Kelly, F.J.; Kraemer, K.; et al. Vitamins E and C are safe across a broad range of intakes. Am. J. Clin. Nutr. 2005, 81, 736–745. [Google Scholar]
  91. Yung, S.; Mayersohn, M.; Robinson, J.B. Ascorbic acid absorption in humans: A comparison among several dosage forms. J. Pharm. Sci. 1982, 71, 282–285. [Google Scholar]
  92. Bhagavan, H.N.; Wolkoff, B.I. Correlation between the disintegration time and the bioavailability of vitamin C tablets. Pharm. Res. 1993, 10, 239–242. [Google Scholar]
  93. Sacharin, R.; Taylor, T.; Chasseaud, L.F. Blood levels and bioavailability of ascorbic acid after administration of a sustained-release formulation to humans. Int. J. Vitam. Nutr. Res. 1977, 47, 68–74. [Google Scholar]
  94. Nyyssonen, K.; Poulsen, H.E.; Hayn, M.; Agerbo, P.; Porkkala-Sarataho, E.; Kaikkonen, J.; Salonen, R.; Salonen, J.T. Effect of supplementation of smoking men with plain or slow release ascorbic acid on lipoprotein oxidation. Eur. J. Clin. Nutr. 1997, 51, 154–163. [Google Scholar]
  95. Bush, M.J.; Verlangieri, A.J. An acute study on the relative gastro-intestinal absorption of a novel form of calcium ascorbate. Res. Commun. Chem. Pathol. Pharmacol. 1987, 57, 137–140. [Google Scholar]
  96. Verlangieri, A.J.; Fay, M.J.; Bannon, A.W. Comparison of the anti-scorbutic activity of l-ascorbic acid and Ester C in the non-ascorbate synthesizing Osteogenic Disorder Shionogi (ODS) rat. Life Sci. 1991, 48, 2275–2281. [Google Scholar]
  97. Gruenwald, J.; Graubaum, H.J.; Busch, R.; Bentley, C. Safety and tolerance of ester-C compared with regular ascorbic acid. Adv. Ther. 2006, 23, 171–178. [Google Scholar]
  98. Knight, A. Systematic reviews of animal experiments demonstrate poor human clinical and toxicological utility. Altern. Lab. Anim. 2007, 35, 641–659. [Google Scholar]
  99. Seok, J.; Warren, H.S.; Cuenca, A.G.; Mindrinos, M.N.; Baker, H.V.; Xu, W.; Richards, D.R.; McDonald-Smith, G.P.; Gao, H.; Hennessy, L.; et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc. Natl. Acad. Sci. USA 2013, 110, 3507–3512. [Google Scholar]
  100. He, F.J.; Nowson, C.A.; MacGregor, G.A. Fruit and vegetable consumption and stroke: Meta-analysis of cohort studies. Lancet 2006, 367, 320–326. [Google Scholar]
  101. Dauchet, L.; Amouyel, P.; Hercberg, S.; Dallongeville, J. Fruit and vegetable consumption and risk of coronary heart disease: A meta-analysis of cohort studies. J. Nutr. 2006, 136, 2588–2593. [Google Scholar]
  102. Steinmetz, K.A.; Potter, J.D. Vegetables, fruit, and cancer prevention: A review. J. Am. Diet. Assoc. 1996, 96, 1027–1039. [Google Scholar]
  103. Riboli, E.; Norat, T. Epidemiologic evidence of the protective effect of fruit and vegetables on cancer risk. Am. J. Clin. Nutr. 2003, 78, 559S–569S. [Google Scholar]
  104. Block, G.; Norkus, E.; Hudes, M.; Mandel, S.; Helzlsouer, K. Which plasma antioxidants are most related to fruit and vegetable consumption? Am. J. Epidemiol. 2001, 154, 1113–1118. [Google Scholar]
  105. Mente, A.; de Koning, L.; Shannon, H.S.; Anand, S.S. A systematic review of the evidence supporting a causal link between dietary factors and coronary heart disease. Arch. Intern. Med. 2009, 169, 659–669. [Google Scholar]
  106. Ye, Z.; Song, H. Antioxidant vitamins intake and the risk of coronary heart disease: Meta-analysis of cohort studies. Eur. J. Cardiovasc. Prev. Rehabil. 2008, 15, 26–34. [Google Scholar]
  107. Knekt, P.; Ritz, J.; Pereira, M.A.; O’Reilly, E.J.; Augustsson, K.; Fraser, G.E.; Goldbourt, U.; Heitmann, B.L.; Hallmans, G.; Liu, S.; et al. Antioxidant vitamins and coronary heart disease risk: A pooled analysis of 9 cohorts. Am. J. Clin. Nutr. 2004, 80, 1508–1520. [Google Scholar]
  108. Lawlor, D.A.; Davey Smith, G.; Kundu, D.; Bruckdorfer, K.R.; Ebrahim, S. Those confounded vitamins: What can we learn from the differences between observational versus randomised trial evidence? Lancet 2004, 363, 1724–1727. [Google Scholar]
  109. Maserejian, N.N.; Giovannucci, E.L.; McVary, K.T.; McKinlay, J.B. Dietary, but not supplemental, intakes of carotenoids and vitamin C are associated with decreased odds of lower urinary tract symptoms in men. J. Nutr. 2011, 141, 267–273. [Google Scholar]
  110. Osganian, S.K.; Stampfer, M.J.; Rimm, E.; Spiegelman, D.; Hu, F.B.; Manson, J.E.; Willett, W.C. Vitamin C and risk of coronary heart disease in women. J. Am. Coll. Cardiol. 2003, 42, 246–252. [Google Scholar]
  111. Agarwal, M.; Mehta, P.K.; Dwyer, J.H.; Dwyer, K.M.; Shircore, A.M.; Nordstrom, C.K.; Sun, P.; Paul-Labrador, M.; Yang, Y.; Merz, C.N. Differing relations to early atherosclerosis between vitamin C from supplements vs. food in the Los Angeles atherosclerosis Study: A prospective cohort study. Open Cardiovasc. Med. J. 2012, 6, 113–121. [Google Scholar]
  112. Henriquez-Sanchez, P.; Sanchez-Villegas, A.; Doreste-Alonso, J.; Ortiz-Andrellucchi, A.; Pfrimer, K.; Serra-Majem, L. Dietary assessment methods for micronutrient intake: A systematic review on vitamins. Br. J. Nutr. 2009, 102, S10–S37. [Google Scholar]
  113. Thompson, F.E.; Byers, T. Dietary assessment resource manual. J. Nutr. 1994, 124, 2245S–2317S. [Google Scholar]
  114. Dehghan, M.; Akhtar-Danesh, N.; McMillan, C.R.; Thabane, L. Is plasma vitamin C an appropriate biomarker of vitamin C intake? A systematic review and meta-analysis. Nutr. J. 2007, 6, 41. [Google Scholar]
  115. Lykkesfeldt, J.; Poulsen, H.E. Is vitamin C supplementation beneficial? Lessons learned from randomised controlled trials. Br. J. Nutr. 2010, 103, 1251–1259. [Google Scholar]
  116. Carr, A.C.; Pullar, J.M.; Moran, S.; Vissers, M.C.M. Bioavailability of vitamin C from kiwifruit in non-smoking males: Determination of ‘healthy’ and ‘optimal’ intakes. J. Nutr. Sci. 2012, 1, e14. [Google Scholar]
  117. Franz, W.L.; Heyl, H.L.; Sands, G.W. Blood ascorbic acid level in bioflavonoid and ascorbic acid therapy of common cold. J. Am. Med. Assoc. 1956, 162, 1224–1226. [Google Scholar]
  118. Arminio, J.J.; Johnston, J.H.; Tebrock, H.E. Usefulness of bioflavonoids and ascorbic acid in treatment of common cold. J. Am. Med. Assoc. 1956, 162, 1227–1233. [Google Scholar]
  119. Baird, I.M.; Hughes, R.E.; Wilson, H.K.; Davies, J.E.; Howard, A.N. The effects of ascorbic acid and flavonoids on the occurrence of symptoms normally associated with the common cold. Am. J. Clin. Nutr. 1979, 32, 1686–1690. [Google Scholar]
  120. Stevenson, D.E.; Hurst, R.D. Polyphenolic phytochemicals—Just antioxidants or much more? Cell. Mol. Life Sci. 2007, 64, 2900–2916. [Google Scholar]
  121. Gao, Y.; Li, W.; Jia, L.; Li, B.; Chen, Y.C.; Tu, Y. Enhancement of (−)-epigallocatechin-3-gallate and theaflavin-3-3′-digallate induced apoptosis by ascorbic acid in human lung adenocarcinoma SPC-A-1 cells and esophageal carcinoma Eca-109 cells via MAPK pathways. Biochem. Biophys. Res. Commun. 2013, 438, 370–374. [Google Scholar]
  122. Calero, C.I.; Beltran Gonzalez, A.N.; Gasulla, J.; Alvarez, S.; Evelson, P.; Calvo, D.J. Quercetin antagonism of GAB receptors is prevented by ascorbic acid through a redox-independent mechanism. Eur. J. Pharmacol. 2013. [Google Scholar] [CrossRef]
Back to TopTop